The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

Participants in the study will be randomly assigned to receive either Nemtabrutinib or one of the other treatments, Ibrutinib or Acalabrutinib, as chosen by the study doctor. The study will last for a period of time during which participants will take the medication and have regular check-ups to monitor their health and the progress of the disease. The study aims to see how well Nemtabrutinib works compared to the other treatments in terms of how long patients live without the disease getting worse and how many patients respond to the treatment.

Throughout the study, the safety of the participants will be closely monitored, and any side effects will be recorded. The study will also look at how long the benefits of the treatment last and how it affects the overall survival of the participants. This research is important to find better ways to treat CLL and SLL and to improve the quality of life for people living with these conditions.

The purpose of the study is to compare how well BGB-16673 works against pirtobrutinib in controlling the disease and to evaluate the safety of both treatments. The study will measure how long patients live without their disease getting worse, which is called progression-free survival. This will be assessed by an independent group of medical experts who will review imaging scans and other test results. The study will also look at overall survival, which means how long patients live overall, and will measure how many patients respond to treatment by having their disease shrink or disappear. Additional measurements include how long the treatment response lasts and how long it takes before patients need another treatment for their disease.

During the study, patients will be randomly assigned to receive either BGB-16673 or pirtobrutinib. Both groups will continue taking their assigned medication for up to 42 months unless their disease gets worse or they experience unacceptable side effects. The study will monitor patients for any unwanted effects of the medications and will track how severe these effects are. Patients will also complete questionnaires about their quality of life, including questions about their physical functioning, symptoms, and overall health status. The study will use computed tomography or magnetic resonance imaging scans to measure disease in patients with small lymphocytic lymphoma, looking for lymph nodes that are larger than normal size.

The purpose of this research is to determine how well NX-5948 works in treating adults with CLL or SLL that has come back or not responded to previous treatments. During the study, participants will receive NX-5948 capsules daily. The maximum daily dose that may be given is 600 milligrams, and treatment may continue for up to 28 days per treatment cycle.

Throughout the study, doctors will monitor participants’ health through regular check-ups and various medical tests. They will look at how the cancer responds to the treatment and keep track of any side effects that may occur. The study will collect information about how long the treatment effects last and how it affects participants’ overall health.

The purpose of the study is to determine which of these two treatment combinations is more effective at preventing disease progression, which is when the cancer begins to grow or spread again. Researchers will also look at overall survival, which is the length of time patients live, and the overall response rate, which measures how many patients see a reduction in the size of their cancer. Additionally, the study will examine undetectable minimal residual disease, a term used to describe a state where very few, if any, cancer cells can be found in the blood or bone marrow using advanced testing.

During the study, participants will be assigned to one of the two treatment groups. They will take the assigned medications orally, meaning by mouth. The study will follow the patients over a period of time to monitor how they respond to the treatments and to track any adverse events, which are side effects or other unexpected medical problems that may occur during the course of the study.

Participants in this study must have received previous treatment with medicines called BTK inhibitors that either did not work, stopped working, or caused side effects that could not be tolerated. They should also have been previously treated with a type of medicine called BCL-2 inhibitors according to local medical practice. The study will randomly assign patients to receive either DZD8586 or one of the doctor’s choice treatments. DZD8586 is given as a tablet taken by mouth daily for up to 36 months. If the doctor chooses idelalisib, it is also taken by mouth daily for up to 36 months. If the doctor chooses the combination treatment, bendamustine is given through a vein and rituximab is given through a vein for up to 24 weeks.

During the study, doctors will monitor how well the treatment controls the cancer by checking for signs of disease progression and measuring how long patients remain free from cancer growth. They will also assess overall survival, quality of life, and safety by monitoring for any side effects or health problems that may occur during treatment. Blood samples will be collected to measure the levels of DZD8586 in the body to understand how the medicine is processed.

The treatments used in this study include several anti-cancer medications: cytarabine, daunorubicin, etoposide, cladribine, mitoxantrone, obinutuzumab, ibrutinib, venetoclax, and fludarabine. Some patients may also receive cyclophosphamide, busulfan, or treosulfan as part of their treatment. The medications are given either through intravenous infusion or as oral tablets, depending on the specific drug.

The main purpose of this study is to determine if less intensive treatment can be as effective as standard treatment in patients who show no signs of remaining disease after initial therapy. The study will monitor patients’ survival, side effects, and whether the disease returns after treatment. Participants will be followed for several years to evaluate the long-term effectiveness of these treatment approaches.

Participants in the study will be randomly assigned to receive either the new medication BGB-16673 or one of the other treatment options. The study will monitor the participants over a period to see how long they live without the disease getting worse. This is known as progression-free survival. The study will also look at other factors, such as overall survival, which is the time from the start of the study until death from any cause, and the response of the disease to the treatment. The study will also track any side effects that occur during the treatment.

The study aims to provide more information about the effectiveness of BGB-16673 compared to the other treatment options. It will help determine which treatment might be better for patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma who have previously been treated with certain other cancer medications. The study is expected to continue until 2030, with recruitment starting in 2025.

The purpose of the study is to compare the effectiveness of these treatments in patients who have not received prior treatment for their CLL or SLL. The study will look at how long patients live without their disease getting worse, which is known as progression-free survival. The trial will also explore how the treatment duration can be adjusted based on the measurement of individual residual disease, which refers to the small number of cancer cells that might remain after treatment.

Participants in the study will receive one of the treatment combinations for a set number of cycles. The study will monitor various outcomes, including the overall response to the treatment, the duration of the response, and the time until the next treatment is needed. Safety will also be closely monitored by tracking any adverse events. The study aims to improve treatment outcomes by tailoring the duration of therapy to each patient’s needs.

The purpose of the study is to see how well the combination of Lisaftoclax and Acalabrutinib works in treating patients with newly diagnosed CLL or SLL. Participants in the study will be randomly assigned to receive either the new drug combination or the standard immunochemotherapy. The study will monitor the participants over a period of time to see how their disease progresses and to check for any side effects from the treatments.

Throughout the study, participants will receive regular check-ups and tests to track their health and the effectiveness of the treatment. The study aims to provide valuable information on whether the new drug combination can offer a better treatment option for patients with CLL or SLL. The study is expected to continue for several years to gather comprehensive data on the outcomes of the treatments being tested.

The purpose of the study is to determine how safe and tolerable AZD0486 is when given to patients with these types of blood cancers. The study will also find the best dose to use in future research. Participants will receive the treatment either through an infusion into a vein or an injection under the skin. The study will be conducted in several phases, starting with a smaller group of participants to assess safety, and then expanding to include more participants to further evaluate the treatment’s effectiveness.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The trial aims to provide valuable information on how well AZD0486 works in treating these blood cancers and to ensure that it is safe for patients. The study is expected to continue until 2026, with recruitment starting in 2025.

Participants in the study will receive either the TL-895 treatment alone or in combination with Navtemadlin. The study will observe how the cancer responds to these treatments over time. Some participants will receive a placebo to compare the effects. The trial is divided into different parts, with some focusing on those who have not been treated before and others on those whose cancer has returned or not responded to previous treatments.

The study will monitor participants for any changes in their condition and any side effects they might experience. The goal is to determine the overall response rate, which means how many people see a reduction in their cancer symptoms. The trial will also look at how long any positive effects last and assess the safety of the treatments. This research aims to find more effective ways to treat these types of blood cancers and improve outcomes for patients in the future.

The purpose of this study is to evaluate how effective and safe the combination of zanubrutinib and obinutuzumab is for patients who have not received treatment for their CLL or SLL before. The study will compare two different schedules for administering obinutuzumab to see which is more effective. Participants will receive these treatments over a period of time, and their health will be monitored to see how well the cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will look at various outcomes, such as the rate of complete remission, which means the cancer is no longer detectable, and how long patients live without the disease getting worse. They will also assess the overall safety of the treatments and any potential side effects. This study aims to provide valuable information on the best way to treat these types of blood cancers with the combination of zanubrutinib and obinutuzumab.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

The purpose of the study is to evaluate the effectiveness of this treatment combination in reducing the presence of cancer cells in the bone marrow. Participants will receive Ibrutinib over a period of 24 cycles, and Obinutuzumab will be given during specific cycles. The study will monitor the patients for 30 days after the completion of the treatment to assess the reduction of cancer cells.

This trial aims to provide valuable information on how well this treatment works for patients with Chronic Lymphocytic Leukemia. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the treatment’s effectiveness. The study will help in understanding whether this combination of medications can be a beneficial option for treating CLL.

The purpose of the study is to test the safety and feasibility of using CLIC-1901 CAR T-cell therapy in patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor the effects of the treatment over a period of time to understand how well it works and to identify any side effects. The trial will also look at how the treatment affects the overall health and survival of the participants.

Throughout the study, researchers will keep track of various health indicators, such as the response of the cancer to the treatment, any side effects experienced, and the overall survival of the participants. The study aims to provide valuable information on the potential benefits and risks of using CAR T-cell therapy in treating these types of blood cancers. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

Participants in the study will receive the medication Lisaftoclax either by itself or together with one of the other mentioned drugs. The study will monitor how well patients tolerate the treatments and will look for any side effects. The goal is to find the best dose of Lisaftoclax that can be safely given to patients. The study will also assess how effective the treatments are in controlling the disease.

Throughout the study, patients will be closely monitored by healthcare professionals. The study will involve regular check-ups and tests to track the progress of the disease and the patient’s response to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study aims to provide valuable information that could lead to better treatment options for people with CLL and SLL.

Participants in the study will be randomly assigned to receive one of the two treatment combinations. The study will be conducted over a period of time, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment. The medications will be administered either as tablets taken by mouth or as an infusion, which is a method of delivering medication directly into the bloodstream through a vein. The study will also include a group receiving a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The trial aims to assess various outcomes, such as how long participants live without the disease getting worse, the overall survival rate, and the response to the treatment. Additionally, the study will look at the quality of life of participants and any side effects they may experience. The trial is expected to continue until 2029, providing valuable information on the best treatment options for people with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

The purpose of the study is to compare the combination of Lisaftoclax and Acalabrutinib with Acalabrutinib alone in patients who have previously been treated for CLL or SLL. Participants will receive either the combination treatment or Acalabrutinib alone. The study will monitor the progression of the disease and assess the safety and effectiveness of the treatments over a period of time. The trial will also include a placebo group to help understand the effects of the treatments better.

Participants will take the medications orally, in the form of tablets or capsules, for a maximum period of 76 weeks. Throughout the study, regular check-ups and assessments will be conducted to monitor the participants’ health and the progression of their disease. The study aims to provide valuable information on whether the combination of Lisaftoclax and Acalabrutinib offers better outcomes for patients with CLL or SLL compared to Acalabrutinib alone.

Participants in the study will be randomly assigned to receive either Zanubrutinib or the combination of Bendamustine and Rituximab. Some participants may also receive Venetoclax. The study will monitor the participants over a period to see how well the treatments work in controlling the disease. The treatments will be given in specific doses and schedules, and participants will be closely observed by medical professionals throughout the study. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study aims to provide valuable information on the progression-free survival of patients, which means the length of time during and after the treatment that the patient lives with the disease without it getting worse. This information will help in understanding the potential benefits and risks of the treatments being studied. Participants will undergo regular check-ups and tests to monitor their health and the effectiveness of the treatment. The study is expected to continue until 2026, providing insights that could improve future treatment options for CLL and SLL.

The study is divided into different phases. In the first phase, patients will receive pirtobrutinib by itself to determine the best dose and to observe any side effects. In the second phase, the study will look at how well the drug works in reducing cancer symptoms. Additionally, there is a part of the study where pirtobrutinib is combined with other drugs like venetoclax and rituximab to see if these combinations are safe and effective. Patients will take the medication in the form of a tablet, which is taken by mouth.

Throughout the study, participants will be monitored for any changes in their health, including blood tests and other assessments to ensure their safety. The study aims to gather information on how the drug affects the body and how it interacts with other treatments. This research is important for developing new treatment options for patients with these types of blood cancers.

The purpose of this study is to evaluate the long-term safety of these CAR T-cell therapies for up to 15 years after the treatment is given. Participants in the study will be monitored over this period to check for any side effects or health changes. This includes looking at the type and frequency of any adverse events, which are unexpected medical problems that occur during treatment. The study will also track the presence of the CAR T-cells in the blood and any changes in the disease status, such as progression or the need for additional cancer treatments.

Throughout the study, researchers will collect information on overall survival and any new health issues that may arise. This information will help determine the long-term effects of the CAR T-cell therapies and their safety for patients who have received them. The study aims to provide valuable insights into how these treatments work over time and their impact on patients’ health.

The purpose of this study is to see how well these treatments work in preventing the cancer from getting worse. Participants will be randomly assigned to one of the two treatment groups. The study will be open-label, meaning both the participants and the researchers will know which treatment is being given. The trial will continue for a period of time to monitor the progression of the disease and the effectiveness of the treatments.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of their treatment. The goal is to determine which combination of medications is more effective in managing CLL and SLL, providing valuable information for future treatment options.

The purpose of the study is to evaluate how effective these treatments are when used in a customized way for patients who have not been treated for CLL before. The study will compare the effects of using Ibrutinib alone and in combination with Venetoclax, with adjustments made to the dosage based on how patients respond to the treatment. This approach aims to tailor the treatment to each patient’s needs, either by reducing the dose proactively or modifying it in response to any side effects.

Participants in the study will receive either Ibrutinib alone or a combination of Ibrutinib and Venetoclax. The study will monitor the patients over a period to see how well the treatments work and how the patients tolerate them. The goal is to find the best way to use these medications to treat CLL effectively while minimizing side effects. The study will also include a comparison with historical data from previous clinical trials to assess the outcomes of the tailored treatment approach.

The purpose of this study is to find out how effective these treatments are when used together in patients whose CLL or SLL has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of Epcoritamab to use with Venetoclax. In the second phase, they will evaluate how well the combination works in reducing the number of cancer cells in the bone marrow, which is the soft tissue inside bones where blood cells are made.

Participants in the study will receive Venetoclax for 26 cycles, which are periods of treatment, along with either 6 or 12 cycles of Epcoritamab. The study will monitor the participants’ health and the effects of the treatment over time. The goal is to see if the combination can help achieve a state where cancer cells are no longer detectable in the bone marrow, which is a sign of effective treatment. The study will also look at how long participants remain free from disease progression and their overall survival during and after the treatment.

The purpose of the study is to evaluate the safety and effectiveness of BCN-CP01 in patients whose CLL or SLL has returned or has not responded to previous treatments. The study is divided into two phases. In the first phase, the focus is on determining the safety of BCN-CP01 and observing any initial signs of its effectiveness. In the second phase, the study aims to further assess how well the treatment works in reducing cancer cells in the body. Participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Throughout the study, participants will undergo regular check-ups and tests to track their health and the response of their cancer to the treatment. The study will help researchers understand if BCN-CP01 can be a viable treatment option for patients with relapsed or refractory CLL or SLL, potentially offering a new way to manage these challenging conditions.

The purpose of this study is to understand if stopping and then restarting Acalabrutinib affects the progression of the disease in frail patients. Participants will take Acalabrutinib for a period, then stop the medication, and later restart it. The study will observe how the disease progresses during this time and whether the treatment helps in maintaining the health of the patients. The trial will also look at the overall survival of patients and their quality of life using a questionnaire.

Throughout the study, the health of the participants will be closely monitored to ensure their safety and to gather information on how effective the treatment is. The trial aims to provide insights into whether this approach can be beneficial for patients with CLL or SLL, especially those who are older and have not been treated before. The study is expected to continue until 2028, allowing researchers to collect comprehensive data on the treatment’s impact over time.